An oral diabetes drug that can slow the progression of Parkinson’s disease has been identified by domestic researchers. As there has been no treatment that can slow the progression of Parkinson’s disease, the results of this study are expected to play a big role in the development of treatments for Parkinson’s disease in the future.
On the 30th, Severance Hospital revealed that a research team of neurology professors Lee Pil-Hyu and Jeong Seung-ho confirmed that early Parkinson’s patients with oral hypoglycemic drug DPP-4 inhibitor showed less damage to dopamine neurons and a good prognosis at follow-up.
The results of this study were published in the latest issue of the journal’Brain’ in the field of clinical neurology. The research team plans to verify the neuroprotective effects of DPP-4 inhibitors in Parkinson’s disease through clinical trials in Parkinson’s disease patients in the future.
DPP-4 inhibitors are drugs that treat diabetes by inhibiting DPP-4, an enzyme that breaks down glucagon-like peptide-1 (GLP-1), which is involved in lipid metabolism, which lowers blood sugar. .
Parkinson’s disease is a representative degenerative brain disease, in which nerve cells that secrete dopamine in a specific part of the brain called black matter located in the midbrain are gradually lost. Motor symptoms in Parkinson’s disease can be controlled with dopamine supplementation drugs, but there are no treatments that change the course of the disease.
The research team divided 697 patients with early Parkinson’s disease into three groups, and compared and analyzed the extent of the loss of dopamine neurons through dopamine positron emission tomography (PET) images according to whether or not to take a DPP-4 inhibitor when diagnosed with Parkinson’s disease.
In addition, 617 Parkinson’s disease patients observed over a long period of time were analyzed for the incidence of motility side effects, such as the increase in dopamine drugs required for symptom control and dyskinesia and exhaustion of drugs during the follow-up period.
As a result of the analysis, it was confirmed that the dopamine transporter density was significantly higher in the patients with diabetes-related Parkinson’s disease who took the DPP-4 inhibitor than those who did not take the DPP-4 inhibitor as well as the Parkinson patients who did not have diabetes. .
In a long-term follow-up study, the research team also confirmed that the group taking the DPP-4 inhibitor had a better prognosis compared to the non-dose group and patients with Parkinson’s disease who did not have diabetes.
Compared to the other groups, the group taking the DPP-4 inhibitor showed significantly less increase in the dose of the dopamine drug, an indicator that reflects the progression of Parkinson’s disease. In addition, the incidence of dyskinesia and drug exhaustion symptoms, which are motor complications related to the progression of Parkinson’s disease, were compared for each group, and the DPP-4 inhibitor group was the lowest.
Professor Seung-ho Jeong said, “Through this study, we were able to indirectly confirm that the DPP-4 inhibitor not only prevents nerve cell loss in Parkinson’s disease, but also has a neuroprotective effect.”
Professor Pil-Hyu Lee said, “There are studies on drugs that inhibit the disease progression of Parkinson’s disease around the world, but DPP-4 inhibitors can play an important role in suppressing the progression of Parkinson’s disease in a situation where no drugs with clear effects have been found. I expect it to be,” he said.